Japanese Ministry of Health will purchase 150 million doses of Novavax coronavirus vaccine from Takeda Pharmaceutical, subject to its approval. Takeda is now building capacity at its facilities in Japan to produce the drug, which will begin distribution in early 2022. Details of the terms of the agreement with the government are confidential.